DIVALPROEX 500 MG
VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG · DIN 02239519 · APOTEX INC
Health Canada status: APPROVED
What is DIVALPROEX?
DIVALPROEX 500 MG contains VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02239519, held by APOTEX INC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as approved, status dated 27-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02239519 |
|---|---|
| Brand name | DIVALPROEX |
| Generic / active ingredient | VALPROIC ACID (DIVALPROEX SODIUM) : 500 MG |
| Manufacturer | APOTEX INC |
| Strength | 500 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AG01 VALPROIC ACID |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 27-May-2021 |
| Original market date | 1999-07-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N03AG01 VALPROIC ACID. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DIVALPROEX | 125 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239698 |
| APO-DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239699 |
| APO-DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239700 |
| APO-VALPROIC ACID | 250 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238048 |
| DEPAKENE | 250 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 00443832 |
| EPIVAL | 125 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596418 |
| EPIVAL | 250 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596426 |
| EPIVAL | 500 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596434 |
| JAMP DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551152 |
| JAMP DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551160 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.